INO
INOVIO PHARMACEUTICALS, INC.Company Information
- Company Name
- INOVIO PHARMACEUTICALS, INC.
- CIK
- CIK0001055726
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- INO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- INO
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2023-06-05
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 37,076
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 33,713,009
- Shares outstanding
- 81,619,113
- Ownership
- 41.31%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 85.71%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | 2 | 9 | 11 | -0 | 3 | 13 | 16 | -2 | -0 | 17 | 20 | -0 | ||||||
| Related Party | 2 | 9 | 11 | -0 | 3 | 13 | 16 | -2 | -0 | 17 | 20 | -0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 32 | 26 | 44 | 37 | 24 | 40 | 66 | 22 | 34 | 20 | 14 | 19 | ||||||
| Short Term Investments | 5 | 11 | 14 | 14 | 23 | 28 | 28 | 63 | 76 | 86 | 131 | 149 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 2 | 3 | 3 | 4 | 2 | 4 | 5 | 5 | 4 | 5 | 5 | ||||||
| Accounts Receivable Net Current | - | - | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 2 | - | ||||||
| Assets Current | 40 | 39 | 61 | 55 | 53 | 72 | 98 | 91 | 118 | 112 | 153 | 175 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 6 | ||||||
| Equity Securities Fv Ni Current And Noncurrent | 0 | 0 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | ||||||
| Operating Lease Right Of Use Asset | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | ||||||
| Other Assets Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets | 49 | 50 | 74 | 69 | 68 | 87 | 113 | 107 | 134 | 129 | 171 | 193 | ||||||
Liabilities Current | ||||||||||||||||||
| Derivative Liabilities Current | 25 | 25 | 29 | 50 | 11 | 10 | 13 | - | - | - | 0 | - | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 40 | 38 | 44 | 70 | 32 | 27 | 35 | 23 | 26 | 23 | 43 | 44 | ||||||
| Operating Lease Liability Noncurrent | 5 | 6 | 7 | 7 | 8 | 9 | 9 | 10 | 11 | 11 | 11 | 11 | ||||||
| Convertible Debt Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 17 | 16 | ||||||
| Liabilities | 45 | 44 | 50 | 77 | 40 | 36 | 45 | 34 | 37 | 35 | 54 | 55 | ||||||
Stockholders Equity | ||||||||||||||||||
| Convertible Debt Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Additional Paid In Capital | 1,845 | 1,841 | 1,840 | 1,812 | 1,803 | 1,802 | 1,799 | 1,785 | 1,783 | 1,749 | 1,741 | 1,737 | ||||||
| Retained Earnings Accumulated Deficit | -1,841 | -1,835 | -1,815 | -1,819 | -1,773 | -1,750 | -1,730 | -1,711 | -1,686 | -1,653 | -1,623 | -1,598 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Stockholders Equity | 4 | 6 | 24 | -8 | 29 | 51 | 69 | 74 | 97 | 94 | 117 | 138 | ||||||
| Liabilities And Stockholders Equity | 49 | 50 | 74 | 69 | 68 | 87 | 113 | 107 | 134 | 129 | 171 | 193 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | - | - | 10 | - | - | - | 10 | - | - | - | 10 | - | ||||||
| Preferred Stock Shares Issued | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Shares Authorized | - | - | 600 | - | - | - | 600 | - | - | - | 600 | - | ||||||
| Common Stock Shares Issued | - | - | 69 | - | - | - | 36 | - | - | - | 23 | - | ||||||
| Shares Outstanding | - | - | 69 | - | - | - | 36 | - | - | - | 23 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialINOVIO PHARMACEUTICALS, INC. (INO) — SEC Financial Statements & Analysis
INOVIO PHARMACEUTICALS, INC. (INO) is a pharmaceutical preparations company, incorporated in DE. INOVIO PHARMACEUTICALS, INC. trades on Nasdaq as: INO. INOVIO PHARMACEUTICALS, INC. (INO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, INOVIO PHARMACEUTICALS, INC. carries a market cap of $89.78M, a P/E ratio of -1.33x, a P/B ratio of 20.54x, a P/S ratio of 1248.52x, an enterprise value of $58.25M, and an EV/EBITDA multiple of -0.75x. On profitability, it posts a gross margin of 149.03%, an operating margin of -132871.32%, a net margin of -130000.00%, a Return on Equity (ROE) of -409.87%, a Return on Assets (ROA) of -114.64%, and a Return on Invested Capital (ROIC) of -287.97%. Per share, it reports EPS of $-0.83, diluted EPS of $-0.83, free cash flow per share of $-0.99, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -23.17% year-over-year, and EPS growth of -63.45% year-over-year. On the balance sheet, it maintains a current ratio of 1.00x, a quick ratio of 0.92x, working capital of $-1.81K, a debt-to-equity ratio of 10.30x, a debt ratio of 0.91, an interest coverage ratio of -632.05x, free cash flow of $-80.78M (TTM), and net debt of $-31.53M. Figures sourced from SEC EDGAR.
- Market Cap
- $89.78M
- P/E TTM
- -1.33x
- EPS TTM
- $-0.83
- P/B TTM
- 20.54x
- ROE TTM
- -409.87%
- ROA TTM
- -114.64%
- Debt To Equity
- 10.30x
- Free Cash Flow TTM
- $-80.78M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is INOVIO PHARMACEUTICALS, INC. in?
INOVIO PHARMACEUTICALS, INC. (INO) operates in the Pharmaceutical Preparations industry.
What exchange does INO trade on?
INOVIO PHARMACEUTICALS, INC. (INO) trades on the Nasdaq.
Where is INOVIO PHARMACEUTICALS, INC. incorporated?
INOVIO PHARMACEUTICALS, INC. is incorporated in DE.
When was INOVIO PHARMACEUTICALS, INC. (INO)'s most recent SEC filing?
INOVIO PHARMACEUTICALS, INC. (INO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is INO's market cap?
INOVIO PHARMACEUTICALS, INC. (INO) has a market capitalization of $89.78M as of 2026-06-30.
What is INO's EPS (earnings per share)?
INOVIO PHARMACEUTICALS, INC. (INO)'s trailing twelve month EPS is $-0.83 as of 2026-06-30.
What is INO's ROE (return on equity)?
INOVIO PHARMACEUTICALS, INC. (INO)'s trailing twelve month Return on Equity (ROE) is -409.87% as of 2026-06-30.
What is INO's ROA (return on assets)?
INOVIO PHARMACEUTICALS, INC. (INO)'s trailing twelve month Return on Assets (ROA) is -114.64% as of 2026-06-30.
What is INO's ROIC (return on invested capital)?
INOVIO PHARMACEUTICALS, INC. (INO)'s trailing twelve month Return on Invested Capital (ROIC) is -287.97% as of 2025-06-30.
What is INO's EV/EBITDA?
INOVIO PHARMACEUTICALS, INC. (INO)'s trailing twelve month EV/EBITDA is -0.75x as of 2026-06-30.